Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Lixte Biotechnology Holdings (LIXT) EPS (Basic) (2016)

Lixte Biotechnology Holdings' EPS (Basic) history spans 7 years, with the latest figure at -$0.01 for Q4 2016.

  • For Q4 2016, EPS (Basic) changed 0.0% year-over-year to -$0.01; the TTM value through Dec 2016 reached -$0.04, up 33.33%, while the annual FY2024 figure was -$1.59, 40.23% up from the prior year.
  • EPS (Basic) reached -$0.01 in Q4 2016 per LIXT's latest filing, roughly flat from -$0.01 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.01 in Q4 2015 to a low of -$0.25 in Q4 2012.
  • Average EPS (Basic) over 5 years is -$0.03, with a median of -$0.01 recorded in 2013.
  • Peak YoY movement for EPS (Basic): plummeted 1160.67% in 2012, then surged 96.03% in 2013.
  • A 5-year view of EPS (Basic) shows it stood at -$0.25 in 2012, then soared by 96.03% to -$0.01 in 2013, then decreased by 0.0% to -$0.01 in 2014, then rose by 0.0% to -$0.01 in 2015, then dropped by 0.0% to -$0.01 in 2016.
  • Per Business Quant, the three most recent readings for LIXT's EPS (Basic) are -$0.01 (Q4 2016), -$0.01 (Q3 2016), and -$0.01 (Q2 2016).